Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

Modified EASIX Score Predicts CRS and ICANS Before Severe Symptoms in Patients With B-Cell...

A modified version of the EASIX (Endothelial Activation and Stress Index) score, when calculated prior to and soon after chimeric antigen receptor (CAR) T-cell...

Rituximab Biosimilars Versus Originator: Comparing Long-Term Survival Benefit in DLBCL

A study published in Blood Advances found the three-year rate of overall survival (OS) was similar between Dutch patients with diffuse large B-cell lymphoma...

Is Dose-Dense BV-ICE an Effective Salvage Option in Relapsed/Refractory Classical Hodgkin Lymphoma?

For patients with relapsed/refractory classical Hodgkin lymphoma (cHL), second-line therapy with a combination of intensive dose-dense brentuximab vedotin (BV) and ifosfamide, carboplatin, and etoposide...

Cognitive Decline Observed Six Months After Chemotherapy in Patients With Lymphoma

Patients with lymphoma tend to report and show signs of worsening cognitive function at six months after chemotherapy compared with healthy controls, according to...

Zanubrutinib Approved for Waldenström Macroglobulinemia

The U.S. Food and Drug Administration (FDA) has approved zanubrutinib for the treatment of adult patients with Waldenström Macroglobulinemia (WM). This approval is based on...

Circulating Tumor DNA After Axi-Cel Stratifies Risk, Predicts Outcomes in LBCL

While many patients with relapsed/refractory large B-cell lymphoma (LBCL) respond to treatment with axicabtagene ciloleucel (axi-cel), only a small subset of these responders experience...

Second-Line Pembrolizumab Plus GVD in Relapsed/Refractory Classical Hodgkin Lymphoma

Second-line pembrolizuab plus intravenous (IV) gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) led to high complete response (CR) rates in patients with relapsed/refractory classical Hodgkin...

Polatuzumab as Bridging or Salvage Therapy for Patients With Relapsed/Refractory LBCL

Polatuzumab vedotin was approved in 2019 in combination with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma (LBCL). It showed...
On location

Ibrutinib Plus Rituximab Shows Efficacy in Indolent Mantle Cell Lymphoma

In the GELTAMO ICML-2015 study, treatment with frontline ibrutinib in combination with rituximab demonstrated high rates of efficacy in patients with indolent mantle cell...
On location

Evaluating a Response-Adapted Rituximab Approach for Patients With Follicular Lymphoma

In patients with follicular lymphoma (FL), standard rituximab maintenance produced better rates of progression-free survival (PFS) than an experimental response-adopted approach, according to results...
Advertisement

Current Issue

October 2021, Volume 7, Issue 12

This issue tells the long story of drug shortages, demystifies transfusion services, and more.

Block title